Theratechnologies inc.
TSX : TH

Theratechnologies inc.

April 17, 2008 09:27 ET

Theratechnologies Receives the 2008 Genesis Innovation Award

MONTREAL, QUEBEC--(Marketwire - April 17, 2008) - Theratechnologies (TSX:TH) is proud to announce that it received the 2008 Genesis Innovation Award by BIOQuebec, at the 8th Annual Genesis Awards Ceremony held yesterday evening in Montreal. Each year, this award recognizes a company with an innovative approach in the Life Sciences industry, which contributes to the notoriety of Quebec's Biotechnology sector.

"We are delighted to have been chosen as the recipients of the Genesis Innovation Award," said Yves Rosconi, President and Chief Executive Officer of Theratechnologies. "This award highlights the innovation and the perseverance of all of our employees in the quest for developing new medicines," added Mr. Rosconi. "Our team can be proud to have been able to demonstrate the promising therapeutic profile of tesamorelin, a molecule developed internally, which is now a great source of hope for patients with HIV-associated lipodystrophy, a serious metabolic disorder, for which there is currently no approved treatment," stated Mr. Rosconi.

Initiated by BIOQuebec, the Genesis Awards seek to recognize Entrepreneurship, Innovation and Technology Transfer of companies and to honor individual pre-eminence among the personalities who have played a key role in the growth of Quebec's Life Sciences industry.

HIV-Associated Lipodystrophy

HIV-associated lipodystrophy is characterized by a change in the distribution of adipose tissue (fat containing tissue), dyslipidemia and glucose intolerance. Visceral adipose tissue accumulation with its concomitant metabolic profile has recently been shown to be a risk factor for cardiovascular diseases in HIV seropositive patients. The changes in fat distribution in lipodystrophy patients include visceral fat accumulation and/or loss of subcutaneous fat, generally in the limbs and in the face. There is no approved treatment available for the accumulation of visceral fat found in patients with HIV-associated lipodystrophy.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information